This article is more than 5 years old. Information may no longer be current.
CIBA Vision sells surgical business unit
ATLANTA — A “significant portion” of CIBA Vision’s surgical business has been sold, the company announced in a press release.
IOLTECH has agreed to purchase CIBA Vision’s Vivarte and Vivarte Presbyopic phakic refractive lens line, the CV232 IOL, and the viscoelastic products UniVisc, VisThesia (a viscoelastic that includes anesthesia) Ophthalin and Ophthalin Plus.
IOLTECH also purchased certain marketing and distribution rights to CIBA’s PRL phakic refractive lens.
Optonol and CIBA have agreed to dissolve their joint marketing efforts for the Ex-Press mini glaucoma shunt. Optonol will assume distribution of the shunt in the United States and Canada. Optonol currently distributes the shunt in the European Union.
CIBA will retain an equity share in Refocus Group, but Refocus will re-assume the licensing and all worldwide marketing rights to its PresView scleral implant and its surgical spacing procedure for the treatment of presbyopia, glaucoma and ocular hypertension.
“We did not have the scale or necessary presence in the market to fully capitalize on the surgical portfolio and this will also allow us to focus on our core lens and lens care business,” said Joe Mallof, CIBA Vision’s chief executive officer, in the news release describing the sale.
CIBA Vision Corp. is the eye care unit of Novartis AG.